Literature DB >> 6510017

Hyperammonemia.

M L Batshaw.   

Abstract

A symptomatic elevation in plasma ammonium concentration, termed hyperammonemia, is associated with numerous congenital and acquired conditions (Table 11). In some cases, such as urea cycle disorders, ammonia is the principal toxin. In other instances, such as portal systemic encephalopathy, it is but one of a number of metabolic disturbances, However, in either case hyperammonemic episodes should be treated aggressively to prevent coma, subsequent brain damage, or death. This involves restricting protein intake, providing adequate calories, and giving agents that remove accumulated nitrogen. Long-term therapy relies on diagnosing the specific disease rate. This rarely requires invasive procedures such as liver biopsy. In most cases measurement of plasma amino acids and urinary organic acids will identify the defect. Treatment involving restriction of nitrogen intake, vitamin supplementation, or stimulation of alternative pathways of waste nitrogen excretion can then be instituted. Early therapy, especially in patients with neonatal-onset hyperammonemia, is imperative to avoid severe brain damage. On this basis, the plasma ammonium level should be determined in virtually every newborn with lethargy, hypotonia, poor feeding, seizures, and/or respiratory distress of unclear origin (Table 12).

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6510017     DOI: 10.1016/0045-9380(84)90047-1

Source DB:  PubMed          Journal:  Curr Probl Pediatr        ISSN: 0045-9380


  19 in total

Review 1.  Ornithine carbamoyl transferase deficiency: findings, models and problems.

Authors:  C Bachmann
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

2.  DNA methylation suppresses expression of the urea cycle enzyme carbamoyl phosphate synthetase 1 (CPS1) in human hepatocellular carcinoma.

Authors:  Hongyan Liu; Huijia Dong; Keith Robertson; Chen Liu
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

3.  Kinetic abnormalities of carbamyl phosphate synthetase-I in a case of congenital hyperammonaemia.

Authors:  I A Qureshi; J Letarte; R Ouellet; B Lemieux; L Cathelineau
Journal:  J Inherit Metab Dis       Date:  1986       Impact factor: 4.982

4.  Fifteen years' experience with 212 hyperammonaemic cases at a metabolic unit.

Authors:  A Tokatli; T Coşkun; I Ozalp
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

5.  N-carbamylglutamate enhancement of ureagenesis leads to discovery of a novel deleterious mutation in a newly defined enhancer of the NAGS gene and to effective therapy.

Authors:  Sandra K Heibel; Nicholas Ah Mew; Ljubica Caldovic; Yevgeny Daikhin; Marc Yudkoff; Mendel Tuchman
Journal:  Hum Mutat       Date:  2011-09-09       Impact factor: 4.878

6.  Citrullinaemia: an infantile form with p-hydroxyphenylpyruvic and p-hydroxyphenyllactic acidurias.

Authors:  M Matsuo; K Saiki; J Tanabe; H Nakamura; T Matsuo
Journal:  J Inherit Metab Dis       Date:  1987       Impact factor: 4.982

7.  Short-term survival of hyperammonemic neonates treated with dialysis.

Authors:  Stefano Picca; Carlo Dionisi-Vici; Andrea Bartuli; Tommaso De Palo; Francesco Papadia; Giovanni Montini; Marco Materassi; Maria Alice Donati; Enrico Verrina; Maria Cristina Schiaffino; Carmine Pecoraro; Emilia Iaccarino; Enrico Vidal; Alberto Burlina; Francesco Emma
Journal:  Pediatr Nephrol       Date:  2014-09-04       Impact factor: 3.714

Review 8.  Optimizing therapy for argininosuccinic aciduria.

Authors:  Sandesh C S Nagamani; Brendan Lee; Ayelet Erez
Journal:  Mol Genet Metab       Date:  2012-07-20       Impact factor: 4.797

9.  Clinical outcomes of neonatal onset proximal versus distal urea cycle disorders do not differ.

Authors:  Nicholas Ah Mew; Lauren Krivitzky; Robert McCarter; Mark Batshaw; Mendel Tuchman
Journal:  J Pediatr       Date:  2012-08-15       Impact factor: 4.406

10.  Influence of intrauterine growth retardation on parameters of liver function in low birth weight infants.

Authors:  G Boehm; D M Müller; B Teichmann; P Krumbiegel
Journal:  Eur J Pediatr       Date:  1990-03       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.